EVMN R&D to Revenue
Evommune, Inc. Common Stock · R&D to Revenue
EVMN R&D to Revenue
Latest reported569.55%period ending
EVMN FY R&D/Revenue (639.94% → 569.55%)
Latest values, visible window
High-resolution chart · PNG
EVMN r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 569.5538% | |
| 917.7714% | |
| 639.94% |